Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

VCYT

Veracyte Inc

Feb 13 • 04:00PM ET

35.77

+0.62 1.76 %

Healthcare • Diagnostics & Research • USA • NASD

Peers: EXAS ILMN GH BIO NTRA MYGN CDNA QGEN FLGT CRL

| Held by: IJR VTI VB ARKK FBT IWM XBI VBK ARKG VXF

Index	RUT	P/E	94.21	EPS (ttm)	0.38	Insider Own	2.16%	Shs Outstand	79.03M	Perf Week	-1.16%
Market Cap	2.83B	Forward P/E	22.86	EPS next Y	1.56	Insider Trans	-10.01%	Shs Float	77.34M	Perf Month	-15.74%
Enterprise Value	2.50B	PEG	0.30	EPS next Q	0.41	Inst Own	110.93%	Short Float	7.28%	Perf Quarter	-15.44%
Income	30.32M	P/S	5.71	EPS this Y	436.38%	Inst Trans	0.43%	Short Ratio	6.58	Perf Half Y	19.07%
Sales	495.14M	P/B	2.25	EPS next Y	-5.90%	ROA	2.29%	Short Interest	5.63M	Perf YTD	-15.04%
Book/sh	15.91	P/C	7.72	EPS next 5Y	76.17%	ROE	2.49%	52W High	50.71 -29.46%	Perf Year	-9.65%
Cash/sh	4.64	P/FCF	28.79	EPS past 3/5Y	- -	ROIC	2.34%	52W Low	22.61 58.20%	Perf 3Y	42.34%
Dividend Est.	-	EV/EBITDA	34.84	Sales past 3/5Y	26.63% 29.93%	Gross Margin	66.85%	Volatility	4.65% 4.75%	Perf 5Y	-52.77%
Dividend TTM	-	EV/Sales	5.05	EPS Y/Y TTM	375.89%	Oper. Margin	9.98%	ATR (14)	1.77	Perf 10Y	538.75%
Dividend Ex-Date	-	Quick Ratio	5.94	Sales Y/Y TTM	16.41%	Profit Margin	6.12%	RSI (14)	36.20	Recom	1.62
Dividend Gr. 3/5Y	- -	Current Ratio	6.23	EPS Q/Q	24.34%	SMA20	-7.33%	Beta	1.92	Target Price	49.18
Payout	0.00%	Debt/Eq	0.03	Sales Q/Q	13.82%	SMA50	-13.73%	Rel Volume	0.76	Prev Close	35.15
Employees	824	LT Debt/Eq	0.03	Earnings	Feb 25 AMC	SMA200	5.23%	Avg Volume	856.06K	Price	35.77
IPO	Oct 30, 2013	Option/Short	Yes / Yes	EPS/Sales Surpr.	59.13% 5.52%	Trades		Volume	654,135	Change	1.76%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-02-25	Resumed	Morgan Stanley	Underweight	$48
Oct-20-25	Initiated	Canaccord Genuity	Hold	$40
Mar-20-25	Initiated	Craig Hallum	Buy	$45
Dec-05-24	Downgrade	Goldman	Buy → Neutral	$38 → $37
Nov-15-24	Initiated	Wolfe Research	Outperform	$50
Oct-16-24	Initiated	UBS	Buy	$43
Oct-10-24	Initiated	Guggenheim	Buy	$40
Feb-23-24	Reiterated	Needham	Buy	$30 → $33
Jan-18-23	Downgrade	Raymond James	Outperform → Mkt Perform
Jan-05-23	Initiated	Scotiabank	Sector Outperform	$33
Jan-07-22	Initiated	Stephens	Overweight	$52
Nov-18-21	Resumed	Goldman	Buy	$60
Jun-15-21	Initiated	Raymond James	Outperform	$45
Feb-18-21	Resumed	Needham	Buy	$88
Jan-28-21	Initiated	Truist	Buy	$61
Nov-10-20	Initiated	KeyBanc Capital Markets	Sector Weight	$48
Sep-09-20	Initiated	Morgan Stanley	Underweight	$35
Jul-31-19	Initiated	Lake Street	Buy	$35
Jul-02-19	Initiated	Needham	Buy	$33
Nov-29-18	Downgrade	Janney	Buy → Neutral

Show Previous Ratings

Today 08:42AM	UBS Reaffirmed Buy Rating on Veracyte (VCYT) After Strong Q4 Testing Revenue (Insider Monkey)
Feb-13-26 09:39AM	Here's How Charles River Stock Is Placed Ahead of Q4 Earnings (Zacks)
08:55AM	How to Find Strong Medical Stocks Slated for Positive Earnings Surprises (Zacks)
Feb-11-26 01:34PM	BD Merges Biosciences & Diagnostics Business With Waters (Zacks)
Feb-10-26 12:20PM	GEHC Launches ReadyFix Fleet Management to Boost ECG Efficiency (Zacks)
11:22AM	Loading…
11:22AM	Will DXCM Deliver Q4 Earnings Beat on G7 Stabilization, Volume Growth? (Zacks)
08:57AM	Labcorp's Q4 Earnings Preview: What's in Store for the Stock? (Zacks)
Feb-09-26 12:58PM	PLSE Shares Positive First-in-Human nPulse Cardiac Catheter Data (Zacks)
10:40AM	GEHC Strengthens AI Fetal Ultrasound via Diagnoly Collaboration (Zacks)
08:02AM	Strength in Cardiovascular Unit Likely to Lift MDT's Q3 Performance (Zacks)
Feb-06-26 09:45AM	Here's How Quest Diagnostics Is Placed Ahead of Q4 Earnings (Zacks)
Feb-05-26 05:40PM	Mettler-Toledo (MTD) Q4 Earnings and Revenues Beat Estimates (Zacks)
12:56PM	Cigna Q4 Earnings Beat Estimates on Higher Specialty Volumes (Zacks)
12:33PM	DXCM Upgrades Stelo With AI-Powered Smart Meal Logging Features (Zacks)
09:35AM	Veracyte (VCYT) Loses 20.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
05:15PM	Loading…
Feb-04-26 05:15PM	Veracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026 (Business Wire)
12:57PM	Quanterix Submits FDA 510(k) for Multi-Analyte Alzheimer's Blood Test (Zacks)
12:51PM	Here's Why You Should Add Masimo Stock to Your Portfolio Now (Zacks)
10:23AM	Edwards Lifesciences' Q4 Earnings on Deck: Here's What to Expect (Zacks)
09:45AM	Here's Why Veracyte (VCYT) is a Strong Growth Stock (Zacks)
08:47AM	Will Pharmacy and Consumer Wellness Segment Lead CVS' Q4 Earnings? (Zacks)
Feb-03-26 01:13PM	GEHC Wins FDA Clearance & CE Mark for Allia Moveo, Marks Global Debut (Zacks)
11:38AM	Zimmer Biomet to Report Q4 Earnings: Here's What to Expect (Zacks)
Feb-02-26 11:57AM	BD & Envetec Showcase Closed-Loop Recycling Solution for Lab Plastics (Zacks)
09:37AM	ILMN Q4 Earnings Preview: NovaSeq X Momentum Likely to Aid Performance (Zacks)
09:13AM	Can Cannabis Strength in Canada Drive Canopy's Q3 Earnings? (Zacks)
Jan-30-26 01:34PM	GRAIL Submits FDA PMA for Galleri Multi-Cancer Early Detection Test (Zacks)
09:55AM	Here's Why Veracyte (VCYT) Is a Great 'Buy the Bottom' Stock Now (Zacks)
08:28AM	HOLX Stock Slips on Q1 Earnings and Revenue Miss, Margins Crash (Zacks)
Jan-29-26 01:32PM	Reasons to Retain Avanos Medical Stock in Your Portfolio Now (Zacks)
01:28PM	Loading…
01:28PM	Organon Completes Divesture of JADA System to Laborie Medical (Zacks)
08:02AM	Here's How Align Technology Is Placed Ahead of Q4 Earnings (Zacks)
Jan-28-26 12:21PM	Elevance Health Q4 Earnings Beat Estimates on Increasing Premiums (Zacks)
11:26AM	QT Imaging & Olea Medical Partner to Enhance Cloud Imaging Platform (Zacks)
09:11AM	Will Higher Dupixent Profits, Eylea HD Sales Drive REGN's Q4 Earnings? (Zacks)
08:55AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
07:46AM	PAHC Q2 Earnings Preview: Animal Health Momentum Likely to Aid Results (Zacks)
07:43AM	Here's How IDEXX Laboratories Is Placed Ahead of Q4 Earnings (Zacks)
07:27AM	Will Robust MedSurg Performance Fuel Boston Scientific's Q4 Earnings? (Zacks)
07:26AM	STERIS' Q3 Earnings on Deck: What's in Store for the Stock? (Zacks)
Jan-27-26 12:19PM	Here's Why You Should Add Merit Medical Stock to Your Portfolio Now (Zacks)
12:07PM	ISRG's da Vinci Gets FDA Nod for Advanced Cardiac Procedures (Zacks)
07:54AM	Resmed's Q2 Earnings on Deck: What's in Store for the Stock? (Zacks)
07:53AM	CLPT Gets EU MDR Certification for ClearPoint Navigation Software (Zacks)
Jan-26-26 12:10PM	Why Veracyte (VCYT) is Poised to Beat Earnings Estimates Again (Zacks)
Jan-23-26 01:50PM	WST Launches Synchrony S1 Prefillable Syringe at Pharmapack (Zacks)
07:17AM	Can Specialty Diagnostics Strength Drive Thermo Fisher's Q4 Earnings? (Zacks)
Jan-22-26 11:08AM	Here's Why You Should Retain Integer Holdings Stock in Your Portfolio (Zacks)
09:50AM	Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term (Zacks)
03:25AM	Veracyte, Inc. (VCYT) Sees Analyst Support as Guggenheim Reaffirms Buy Rating (Insider Monkey)
Jan-21-26 01:29PM	Centene Expands Palliative Care Access in Ohio Through Tuesday Health (Zacks)
11:43AM	BD Gets FDA 510(k) Approval for EnCor EnCompass Breast Biopsy System (Zacks)
Jan-19-26 12:40PM	Elekta Wins FDA Nod for Evo CT-Linac, Boosting U.S. Radiation Oncology (Zacks)
07:37AM	Will Robust Adult Nutrition Business Performance Fuel ABT's Q4 Earnings? (Zacks)
Jan-14-26 01:11PM	Option Care Health Stock Earns Healthy RS Rating Upgrade (Investor's Business Daily)
Jan-13-26 10:45AM	NTRA & NVDA Partner to Improve AI Models for Precision Medicine (Zacks)
Jan-12-26 08:57AM	RVTY & Eli Lilly Partner to Expand Access to AI Drug Discovery Models (Zacks)
Jan-11-26 04:30PM	Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results (Business Wire)
Jan-08-26 09:00AM	The Zacks Rank Explained: How to Find Strong Buy Medical Stocks (Zacks)
Jan-07-26 12:24PM	BFLY to Extend 3D Imaging Capabilities to Butterfly Garden Developers (Zacks)
Jan-05-26 12:51PM	Here's Why You Should Retain Masimo Stock in Your Portfolio Now (Zacks)
Dec-31-25 07:25AM	Smart Oncology: 5 Stocks Chasing the $317B Prize (PR Newswire)
Dec-30-25 11:48PM	Morgan Stanley Initiates Coverage Of Veracyte, Inc. (VCYT) (Insider Monkey)
10:42AM	RBOT Enters Strategic Software Partnership to Streamline Development (Zacks)
05:48AM	Zacks Industry Outlook Highlights Veracyte, IDEXX Laboratories and Intuitive Surgical (Zacks)
Dec-29-25 04:30PM	Veracyte to Participate in the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
07:23AM	3 Medical Instrument Stocks to Counter Industry Woes Using GenAI (Zacks)
Dec-26-25 12:20PM	EW Wins FDA Approval for SAPIEN M3 as First Transseptal TMVR Therapy (Zacks)
Dec-23-25 02:08PM	Is This the Right Time to Add Veracyte Stock to Your Portfolio? (Zacks)
Dec-17-25 12:01PM	HOLX's Genius AI Mammography Flags Missed Breast Cancer Cases (Zacks)
Dec-11-25 10:06AM	ISRG Gets FDA Clearance to Use da Vinci SP Robot for General Surgeries (Zacks)
Dec-10-25 12:40PM	PLSE Starts Research Work on nPulse Technology to Treat Thyroid Tumor (Zacks)
08:59AM	Here's Why You Should Add Cencora Stock to Your Portfolio Now (Zacks)
Dec-08-25 08:23AM	Beat the Market the Zacks Way: Veracyte, Las Vegas Sands, 3M in Focus (Zacks)
Dec-03-25 11:59AM	EHC Opens New Lake Worth Rehab Hospital to Meet Rising Demand (Zacks)
Dec-02-25 09:45AM	Why Veracyte (VCYT) is a Top Growth Stock for the Long-Term (Zacks)
Nov-19-25 12:24PM	TDOC Partners With TytoCare to Expand At-Home Exam Capabilities (Zacks)
Nov-13-25 11:07AM	Ensign Group Shares Decline 2.2% Despite Q3 Earnings Beat (Zacks) -5.74%
Nov-11-25 12:24PM	Encompass Health Shares Down 8% Despite Q3 Earnings & Revenue Beat (Zacks)
07:26AM	VCYT Stock Gains on Q3 Earnings and Revenue Beat, '25 View Up (Zacks)
Nov-10-25 12:55PM	Tenet Healthcare Shares Down 5% Despite Q3 Earnings Beat (Zacks)
Nov-06-25 12:09PM	Pediatrix Medical Q3 Earnings Beat Estimates on Declining Expenses (Zacks) -9.45%
08:30AM	Veracyte to Participate in Upcoming Investor Conferences (Business Wire)
Nov-05-25 12:03AM	Veracyte Inc (VCYT) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com) +27.46%
Nov-04-25 06:25PM	Veracyte (VCYT) Q3 Earnings and Revenues Beat Estimates (Zacks)
05:31PM	Veracyte: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Veracyte Announces Third Quarter 2025 Financial Results (Business Wire)
Nov-03-25 04:15PM	Veracyte Announces First Publications Using Afirma GRID Research Tool To Help Usher in Next Generation of Thyroid Nodule Testing (Business Wire)
07:31AM	What To Expect From Veracyte Inc (VCYT) Q3 2025 Earnings (GuruFocus.com)
Oct-31-25 10:17AM	EW Stock Gains on Q3 Earnings and Revenue Beat, Margins Crash (Zacks)
Oct-30-25 12:24PM	ALGN Stock Up on Q3 Earnings and Revenue Beat, Margins Crash (Zacks)
Oct-29-25 09:08AM	CHE Stock Falls on Q3 Earnings and Revenue Miss, Margins Crash (Zacks)
Oct-28-25 10:01AM	LH Q3 Earnings Beat, Revenues Miss, '25 Sales View Cut, Stock Down (Zacks)
Oct-24-25 01:53PM	ITGR Shares Down Despite Q3 Earnings & Revenues Beat Estimates (Zacks)
Oct-22-25 10:56AM	ISRG Stock Gains on Q3 Earnings & Revenue Beat, Gross Margin Declines (Zacks)
09:23AM	Boston Scientific Beats on Q3 Earnings, Raises 2025 View, Stock Up (Zacks)
09:16AM	Thermo Fisher's Q3 Earnings & Revenues Top Estimates, Stock Climbs (Zacks)
08:30AM	Here's How Much a $1000 Investment in Veracyte Made 10 Years Ago Would Be Worth Today (Zacks)
Oct-21-25 09:29AM	Quest Diagnostics Stock Up on Q3 Earnings & Revenue Beat, Margins Rise (Zacks)
Oct-16-25 09:35AM	Veracyte (VCYT) Crossed Above the 20-Day Moving Average: What That Means for Investors (Zacks)

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
McGuire Annie	SVP, General Counsel	Dec 16 '25	Sale	43.13	10,739	463,204	67,760	Dec 17 04:35 PM
ANN MCGUIRE	Officer	Dec 16 '25	Proposed Sale	43.53	10,739	467,469		Dec 16 04:30 PM
EASTHAM KARIN	Director	Dec 05 '25	Option Exercise	7.77	20,000	155,400	33,554	Dec 08 04:34 PM
EASTHAM KARIN	Director	Dec 05 '25	Sale	45.45	20,000	908,923	13,554	Dec 08 04:34 PM
KARIN EASTHAM	Director	Dec 05 '25	Proposed Sale	47.41	20,000	948,200		Dec 05 04:26 PM
McGuire Annie	SVP, General Counsel	Dec 04 '25	Sale	47.30	1,422	67,261	78,499	Dec 04 07:44 PM
Chambers Rebecca	Chief Financial Officer	Dec 04 '25	Sale	46.84	13,278	621,955	109,496	Dec 04 07:44 PM
Stapley Marc	Chief Executive Officer	Dec 04 '25	Sale	47.09	7,668	361,076	318,603	Dec 04 07:44 PM
Leite John	Chief Commercial Officer-CLIA	Dec 04 '25	Sale	47.51	1,278	60,718	82,113	Dec 04 07:43 PM
ANN MCGUIRE	Officer	Dec 04 '25	Proposed Sale	47.75	1,422	67,900		Dec 04 04:39 PM
REBECCA CHAMBERS	Officer	Dec 04 '25	Proposed Sale	47.75	13,278	634,024		Dec 04 04:39 PM
MARC STAPLEY	Director	Dec 04 '25	Proposed Sale	47.75	7,668	366,147		Dec 04 04:38 PM
Leite John	Chief Commercial Officer-CLIA	Nov 25 '25	Sale	50.00	2,808	140,400	86,291	Nov 26 04:27 PM
JONES EVAN/ FA	Director	Nov 25 '25	Sale	50.25	1,106	55,576	29,362	Nov 26 04:27 PM
Evan Jones	Director	Nov 25 '25	Proposed Sale	49.38	5,000	246,900		Nov 25 07:25 PM
John Leite	Officer	Nov 25 '25	Proposed Sale	46.70	4,086	190,816		Nov 25 04:28 PM
Holstein Jens	Director	Nov 20 '25	Sale	42.36	10,000	423,563	27,199	Nov 21 04:19 PM
JENS HOLSTEIN	Director	Nov 20 '25	Proposed Sale	42.36	10,000	423,563		Nov 20 04:03 PM
Wygant Jonathan	VP, Chief Accounting Officer	Nov 07 '25	Sale	40.21	5,818	233,929	43,847	Nov 12 04:25 PM
Wygant Jonathan	VP, Chief Accounting Officer	Nov 10 '25	Sale	42.33	5,102	215,978	38,745	Nov 12 04:25 PM
McGuire Annie	SVP, General Counsel	Nov 05 '25	Sale	40.00	6,466	258,640	82,973	Nov 07 04:10 PM
JONES EVAN/ FA	Director	Nov 05 '25	Option Exercise	6.94	30,000	208,200	73,664	Nov 07 04:10 PM
JONES EVAN/ FA	Director	Nov 05 '25	Sale	45.06	43,196	1,946,288	30,468	Nov 07 04:10 PM
EASTHAM KARIN	Director	Nov 05 '25	Sale	40.02	9,674	387,191	13,554	Nov 07 04:10 PM
Chambers Rebecca	Chief Financial Officer	Nov 05 '25	Sale	41.00	7,000	287,000	126,158	Nov 07 04:10 PM
Evan Jones	Director	Nov 05 '25	Proposed Sale	46.04	43,196	1,988,744		Nov 05 09:47 PM
KARIN EASTHAM	Director	Nov 05 '25	Proposed Sale	36.12	9,674	349,425		Nov 05 04:18 PM
ANN MCGUIRE	Officer	Nov 05 '25	Proposed Sale	36.12	6,466	233,552		Nov 05 04:18 PM
REBECCA CHAMBERS	Officer	Nov 05 '25	Proposed Sale	36.12	7,000	252,840		Nov 05 04:17 PM
Febbo Phillip G.	Chief Scientific & Med Officer	Oct 06 '25	Sale	36.02	8,349	300,709	92,441	Oct 07 04:27 PM
PHILLIP FEBBO	Officer	Oct 06 '25	Proposed Sale	36.00	8,349	300,564		Oct 06 04:19 PM
Leite John	Chief Commercial Officer-CLIA	Oct 01 '25	Sale	35.00	2,539	88,865	89,099	Oct 03 04:16 PM
EPSTEIN ROBERT S	Director	Oct 01 '25	Option Exercise	7.94	10,000	79,400	83,919	Oct 03 04:16 PM
EPSTEIN ROBERT S	Director	Oct 01 '25	Sale	35.08	21,473	753,204	62,446	Oct 03 04:16 PM
McGuire Annie	SVP, General Counsel	Oct 01 '25	Sale	35.00	2,160	75,608	89,439	Oct 03 04:16 PM
ROBERT S EPSTEIN	Director	Oct 01 '25	Proposed Sale	34.33	21,473	737,168		Oct 01 04:27 PM
John Leite	Officer	Oct 01 '25	Proposed Sale	34.33	2,539	87,164		Oct 01 04:27 PM
ANN MCGUIRE	Officer	Oct 01 '25	Proposed Sale	34.33	2,160	74,153		Oct 01 04:26 PM
McGuire Annie	SVP, General Counsel	Sep 19 '25	Sale	33.69	2,283	76,920	91,599	Sep 23 04:18 PM
ANN MCGUIRE	Officer	Sep 19 '25	Proposed Sale	33.23	2,283	75,864		Sep 19 04:25 PM
Stapley Marc	Chief Executive Officer	Sep 04 '25	Sale	30.41	7,667	233,133	334,185	Sep 08 04:33 PM
MARC STAPLEY	Director	Sep 04 '25	Proposed Sale	30.62	7,667	234,764		Sep 04 04:26 PM
EASTHAM KARIN	Director	Jun 13 '25	Sale	26.66	4,590	122,388	13,907	Jun 17 04:21 PM
Bhanji Muna	Director	Jun 13 '25	Sale	26.67	4,589	122,367	29,989	Jun 17 04:21 PM
KARIN EASTHAM	Director	Jun 13 '25	Proposed Sale	26.69	4,590	122,507		Jun 13 04:46 PM
MUNA BHANJI	Director	Jun 13 '25	Proposed Sale	26.69	4,589	122,480		Jun 13 04:45 PM
Leite John	Chief Commercial Officer-CLIA	Jun 04 '25	Sale	27.20	2,809	76,410	94,540	Jun 06 04:19 PM
JOHN LEITE	Officer	Jun 04 '25	Proposed Sale	26.50	2,809	74,438		Jun 04 04:21 PM
Leite John	Chief Commercial Officer-CLIA	Mar 07 '25	Sale	31.66	7,411	234,630	100,249	Mar 10 04:43 PM
JOHN LEITE	Officer	Mar 07 '25	Proposed Sale	32.51	7,411	240,932		Mar 07 04:17 PM
ANN MCGUIRE	Officer	Mar 04 '25	Proposed Sale	33.56	1,142	38,326		Mar 04 05:12 PM
MARC STAPLEY	Director	Mar 04 '25	Proposed Sale	33.56	52,697	1,768,511		Mar 04 05:07 PM
PHILLIP FEBBO	Officer	Mar 04 '25	Proposed Sale	33.56	8,037	269,722		Mar 04 05:07 PM
Leite John	Chief Commercial Officer-CLIA	Feb 27 '25	Sale	33.84	5,746	194,445	79,070	Mar 03 04:30 PM

Open in Screener

NKTR

Nektar Therapeutics

Feb 13 • 04:00PM ET

71.33

+0.33 0.46 %

Healthcare • Biotechnology • USA • NASD

NKTR Nektar Therapeutics daily Stock Chart

Peers: AMGN BIIB VRTX GILD REGN INCY IONS SRPT EXEL NBIX

| Held by: VTI VXF XPH SCHA PRFZ IHE LFSC VHT ITOT SCHB

Index	-	P/E	-	EPS (ttm)	-7.94	Insider Own	1.46%	Shs Outstand	20.34M	Perf Week	93.78%
Market Cap	1.45B	Forward P/E	-	EPS next Y	-9.87	Insider Trans	-10.01%	Shs Float	20.04M	Perf Month	97.64%
Enterprise Value	1.35B	PEG	-	EPS next Q	-2.42	Inst Own	80.69%	Short Float	16.40%	Perf Quarter	23.69%
Income	-120.74M	P/S	23.18	EPS this Y	-15.44%	Inst Trans	40.80%	Short Ratio	3.21	Perf Half Y	167.25%
Sales	62.60M	P/B	16.48	EPS next Y	1.74%	ROA	-39.63%	Short Interest	3.29M	Perf YTD	68.71%
Book/sh	4.33	P/C	5.37	EPS next 5Y	-9.84%	ROE	-180.24%	52W High	72.31 -1.36%	Perf Year	433.23%
Cash/sh	13.28	P/FCF	-	EPS past 3/5Y	41.29% 25.49%	ROIC	-52.50%	52W Low	0.43 16411.57%	Perf 3Y	54.39%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-1.15% -3.00%	Gross Margin	85.92%	Volatility	13.34% 8.32%	Perf 5Y	-79.20%
Dividend TTM	-	EV/Sales	21.53	EPS Y/Y TTM	36.87%	Oper. Margin	-217.83%	ATR (14)	4.88	Perf 10Y	-58.79%
Dividend Ex-Date	-	Quick Ratio	4.24	Sales Y/Y TTM	-32.79%	Profit Margin	-192.87%	RSI (14)	81.88	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	4.24	EPS Q/Q	29.43%	SMA20	66.57%	Beta	-1.11	Target Price	123.43
Payout	-	Debt/Eq	1.96	Sales Q/Q	-51.13%	SMA50	58.36%	Rel Volume	2.15	Prev Close	71.00
Employees	61	LT Debt/Eq	1.70	Earnings	Nov 06 AMC	SMA200	91.05%	Avg Volume	1.02M	Price	71.33
IPO	May 03, 1994	Option/Short	Yes / Yes	EPS/Sales Surpr.	30.35% 17.26%	Trades		Volume	2,203,367	Change	0.46%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-10-26	Upgrade	William Blair	Mkt Perform → Outperform
Nov-26-25	Initiated	Citigroup	Buy	$102
Jun-24-25	Reiterated	H.C. Wainwright	Buy	$6.50 → $120
Jun-24-25	Reiterated	BTIG Research	Buy	$60 → $100
Apr-11-25	Upgrade	Jefferies	Hold → Buy	$2
Mar-14-25	Upgrade	Oppenheimer	Perform → Outperform	$6
Jan-08-25	Initiated	B. Riley Securities	Buy	$4
Dec-10-24	Initiated	H.C. Wainwright	Buy	$6.50
Nov-04-24	Initiated	Piper Sandler	Overweight	$7
Sep-30-24	Resumed	BTIG Research	Buy	$4
Jun-28-24	Initiated	Rodman & Renshaw	Buy	$2
Nov-20-23	Resumed	JP Morgan	Underweight
Nov-09-23	Upgrade	TD Cowen	Market Perform → Outperform
May-10-23	Upgrade	Jefferies	Underperform → Hold	$1.50 → $1
Feb-24-23	Downgrade	Jefferies	Hold → Underperform	$3.20 → $1.50
Aug-08-22	Downgrade	JP Morgan	Neutral → Underweight
May-31-22	Resumed	Jefferies	Hold	$12 → $4
Apr-18-22	Downgrade	Goldman	Neutral → Sell	$3
Mar-15-22	Downgrade	Mizuho	Buy → Neutral	$35 → $8
Mar-15-22	Downgrade	Cowen	Outperform → Market Perform

Show Previous Ratings

Feb-13-26 04:15PM	Nektar Therapeutics Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
Feb-11-26 10:23PM	Nektar Therapeutics Announces Pricing of Upsized $400 Million Public Offering (PR Newswire) +18.48% +7.01%
08:08AM	Nektar (NKTR) Soars 51.1%: Is Further Upside Left in the Stock? (Zacks)
07:42AM	Nektars stock rises 51% on Phase II Rezpeg AD maintenance win (Clinical Trials Arena)
07:35AM	Why Is Nektar Therapeutics Stock Gaining Wednesday? (Benzinga)
02:07AM	Loading…
02:07AM	Nektar Therapeutics Touts 52-Week ResPEG Data in Atopic Dermatitis, Eyes Phase 3 Launch in Q2 (MarketBeat)
Feb-10-26 04:07PM	Has Dupixent Met Its Match? Rivals Nektar, Evommune Catapult On Eczema Results. (Investor's Business Daily) +51.07%
04:05PM	Nektar Therapeutics Announces Proposed Public Offering (PR Newswire)
11:57AM	Nektar Therapeutics Stock Is Trending Tuesday: What's Going On? (Benzinga)
07:13AM	Nektar, continuing comeback, says eczema drugs effects hold up in follow-up study (BioPharma Dive)
07:00AM	New REZOLVE-AD Maintenance Data in Atopic Dermatitis Demonstrate Rezpegaldesleukin Resulted in Durable and New Responses Across Key Disease Measurements with Both Monthly and Quarterly Dosing (PR Newswire)
Feb-09-26 04:15PM	Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Maintenance Period for its REZOLVE-AD Phase 2b Study of Rezpegaldesleukin in Atopic Dermatitis on February 10, 2026 (PR Newswire)
Feb-02-26 10:02PM	Nektar Therapeutics (NKTR): A Bull Case Theory (Insider Monkey)
Jan-30-26 04:10PM	Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +5.96%
Jan-08-26 09:36AM	Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceuticals and Marker Therapeutics (Zacks)
08:45AM	Loading…
Jan-07-26 08:45AM	5 Small Drug Stocks to Buy as Industry Recovery Picks Up (Zacks)
Jan-05-26 05:05PM	Ignore Nektar Therapeutics Stock in 2026 and Load Up on This One Instead (Motley Fool)
Dec-26-25 02:33AM	The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar (Zacks)
Dec-24-25 10:51AM	4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow (Zacks)
Dec-21-25 07:31AM	Strong REZOLVE-AA Study Results Drive Analyst Confidence in Nektar Therapeutics (NKTR) (Insider Monkey)
Dec-16-25 07:30AM	REZOLVE-AA Phase 2b Study of Rezpegaldesleukin Establishes Proof-of-Concept in Patients with Severe-to-Very-Severe Alopecia Areata (PR Newswire) -7.77%
06:24AM	Nektar sees silver lining as autoimmune drug narrowly misses in alopecia study (BioPharma Dive)
Dec-15-25 06:00PM	Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025 (PR Newswire)
Dec-08-25 12:00PM	Here's Why Nektar Therapeutics (NKTR) is a Great Momentum Stock to Buy (Zacks)
Dec-05-25 06:00PM	Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Dec-01-25 09:55AM	Wall Street Analysts Believe Nektar (NKTR) Could Rally 64.53%: Here's is How to Trade (Zacks) -6.29%
Nov-26-25 09:43AM	Autodesk upgraded, Nio downgraded: Wall Street's top analyst calls (The Fly) +8.85%
Nov-23-25 07:02AM	Is Nektar Therapeutics (NKTR) The Hottest SMID-Cap Stock to Buy Now? (Insider Monkey)
Nov-20-25 06:57AM	Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know. (Motley Fool) -8.68%
Nov-13-25 09:55AM	Does Nektar (NKTR) Have the Potential to Rally 62.75% as Wall Street Analysts Expect? (Zacks) -6.45%
05:45PM	Loading…
Nov-08-25 05:45PM	New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting (PR Newswire)
Nov-07-25 10:11AM	Nektar Therapeutics Q3 Loss Narrower Than Expected, Revenues Rise Y/Y (Zacks)
12:07AM	Nektar Therapeutics (NKTR) Q3 2025 Earnings Call Highlights: Strong Cash Position and Promising ... (GuruFocus.com)
Nov-06-25 05:55PM	Nektar Therapeutics (NKTR) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
05:06PM	Nektar: Q3 Earnings Snapshot (Associated Press Finance)
04:15PM	Nektar Therapeutics Reports Third Quarter 2025 Financial Results (PR Newswire)
Nov-03-25 10:00AM	Guardian Pharmacy Services (GRDN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks) -7.72%
Oct-30-25 06:00PM	Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London (PR Newswire) +5.32%
10:00AM	Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-28-25 06:00PM	Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets (PR Newswire)
09:55AM	Wall Street Analysts See a 50.01% Upside in Nektar (NKTR): Can the Stock Really Move This High? (Zacks)
Oct-26-25 06:06AM	Nektar Therapeutics Data from REZOLVE-AD Study Accepted for Late-Breaking Oral Presentation (Insider Monkey)
Oct-22-25 08:00AM	Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting (PR Newswire)
Oct-13-25 08:37AM	This Stock Is Up By 285% This Year But Could Still Jump By 53%, According to Wall Street (Motley Fool) +5.63%
Oct-05-25 08:41AM	Here's Why Nektar Therapeutics Stock Rocketed 90.6% Higher in September (Motley Fool)
Sep-25-25 05:22AM	Zevra Therapeutics (ZVRA) Soars 10.4%: Is Further Upside Left in the Stock? (Zacks) -7.81%
Sep-21-25 06:43PM	These 2 Healthcare Stocks Are Up Over 100% in a Month. Can They Keep Climbing? (Motley Fool)
Sep-18-25 05:34PM	Why Nektar Therapeutics Stock Zoomed More Than 15% Higher Today (Motley Fool) +15.06% -6.16%
12:23PM	EADV 25: Nektar presents data from AD candidate that sent stocks flying (Clinical Trials Arena)
08:45AM	Nektar Presents New Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin in Late-Breaker Oral Presentation at EADV 2025 (PR Newswire)
Sep-09-25 07:00AM	Nektar Announces REZOLVE-AD Phase 2b Results for Rezpegaldesleukin Selected for Late-Breaker Oral Presentation at EADV 2025 (PR Newswire) +9.56%
Sep-08-25 11:27AM	NKTR Shares Surge 38.2% in a Week: Here's What You Should Know (Zacks) +10.33%
Sep-05-25 01:32PM	Why Nektar Therapeutics Rippled Higher This Week (Motley Fool) +11.67%
Sep-03-25 07:00PM	Nektar Therapeutics to Participate in Two Investor Conferences in September (PR Newswire) +26.02%
Aug-14-25 12:22PM	Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment (PR Newswire)
Aug-08-25 06:15PM	Why Nektar Therapeutics Stock Popped 6% on Friday (Motley Fool) +6.02%
11:45AM	Nektar Q2 Loss Narrower Than Expected, Revenues Fall Y/Y (Zacks)
Aug-07-25 05:30PM	Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:33PM	Nektar: Q2 Earnings Snapshot (Associated Press Finance)
04:15PM	Nektar Therapeutics Reports Second Quarter 2025 Financial Results (PR Newswire)
Aug-05-25 06:10PM	Rigel Pharmaceuticals (RIGL) Q2 Earnings and Revenues Surpass Estimates (Zacks)
Aug-04-25 11:55AM	Nektar Gears Up to Report Q2 Earnings: What's in the Cards? (Zacks)
10:00AM	Journey Medical Corporation (DERM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-31-25 06:00PM	Nektar to Announce Financial Results for the Second Quarter on Thursday, August 7, 2025, After Close of U.S.-Based Financial Markets (PR Newswire) +5.90%
Jul-29-25 09:00AM	Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Severe-to-Very Severe Alopecia Areata (PR Newswire)
01:31AM	Nektar Therapeutics (NKTR) Announced Positive results for Rezpegaldesleukin (Insider Monkey)
Jul-21-25 11:02AM	3 Bullish Biotech Stocks With Explosive Growth Trends (MarketBeat)
Jul-06-25 04:01AM	Nektar Therapeutics Reports Positive Phase 2b Results for Eczema Treatment Rezpegaldesleukin (Insider Monkey)
Jul-03-25 07:00PM	Why Nektar Therapeutics Stock Dived by 3% Today (Motley Fool) -5.21%
Jul-02-25 04:15PM	Nektar Therapeutics Announces Closing of $115 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
Jul-01-25 07:17AM	Nektar Therapeutics Announces Pricing of $100 Million Public Offering (PR Newswire)
Jun-30-25 04:02PM	Nektar Therapeutics Announces Proposed Public Offering (PR Newswire)
02:21PM	Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains (MarketBeat)
Jun-28-25 08:15AM	Nektar Jumps 157% on Drug Trial Data-Can It Go Even Higher? (MarketBeat)
Jun-25-25 06:45PM	Why Nektar Therapeutics Stock Was Red-Hot Today (Motley Fool) +19.10%
12:20PM	Wainwright sets over $100 target for Nektar on paradigm-shifting data (TipRanks)
11:30AM	NKTR Stock Soars as Lead Drug Meets Goal in Atopic Dermatitis Study (Zacks)
Jun-24-25 04:23PM	Nektar Therapeutics Launches After Unearthing 'A New Biology' In Eczema Treatment (Investor's Business Daily) +156.29%
10:54AM	Nektar Therapeutics Stock Doubles After Promising Eczema Drug Trial Results (Investopedia)
10:40AM	Strength Seen in Nektar (NKTR): Can Its 12.1% Jump Turn into More Strength? (Zacks)
09:07AM	Nektar Therapeutics Launches By Triple Digits On Eczema Grand Slam (Investor's Business Daily)
07:30AM	REZOLVE-AD Phase 2b Study of Rezpegaldesleukin Meets Primary and Key Secondary Endpoints in Patients with Moderate-to-Severe Atopic Dermatitis (PR Newswire)
Jun-23-25 04:30PM	Nektar to Announce Top-line Data from the 16-Week Induction Period in REZOLVE-AD Phase 2b Study of Rezpegaldesleukin, a Regulatory T-cell Proliferator, in Atopic Dermatitis on June 24, 2025 (PR Newswire) +12.10%
May-13-25 05:00PM	Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference (PR Newswire)
May-09-25 02:29PM	Q1 2025 Nektar Therapeutics Earnings Call (Thomson Reuters StreetEvents)
09:08AM	Nektar Q1 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down (Zacks)
03:46AM	Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Highlights: Advancements in Immunology and ... (GuruFocus.com)
May-08-25 06:25PM	Nektar Therapeutics (NKTR) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
05:19PM	Nektar: Q1 Earnings Snapshot (Associated Press Finance)
04:15PM	Nektar Therapeutics Reports First Quarter 2025 Financial Results (PR Newswire)
May-07-25 05:20PM	Nektar Therapeutics Q1 2025 Earnings Preview (Seeking Alpha) -5.67%
May-01-25 06:00PM	Nektar to Announce Financial Results for the First Quarter on Thursday, May 8, 2025, After Close of U.S.-Based Financial Markets (PR Newswire)
10:01AM	Will Nektar Therapeutics (NKTR) Report Negative Q1 Earnings? What You Should Know (Zacks)
Apr-11-25 02:29PM	Jefferies Upgrades Nektar Therapeutics to Buy, Doubles Price Target to $2.00 (GuruFocus.com) +23.76%
11:30AM	Why Is Nektar (NKTR) Down 38.8% Since Last Earnings Report? (Zacks)
Mar-22-25 06:57PM	Nektar Therapeutics (NKTR): Among Stocks Wall Street Is Calling Bullish Amid Market Turmoil (Insider Monkey)
Mar-20-25 06:00PM	Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference (PR Newswire)
Mar-14-25 07:33AM	Nektar Therapeutics (NKTR) Q4 Earnings Miss Estimates (Revised) (Zacks) +9.98%
Mar-13-25 12:06PM	Q4 2024 Nektar Therapeutics Earnings Call (Thomson Reuters StreetEvents)
03:09AM	Nektar Therapeutics (NKTR) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... (GuruFocus.com)

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Zalevsky Jonathan	Chief R&D Officer	Jan 20 '26	Sale	35.67	3,867	137,936	21,354	Jan 22 07:31 PM
Zalevsky Jonathan	Officer	Jan 20 '26	Proposed Sale	35.67	3,867	137,946		Jan 20 04:21 PM
Zalevsky Jonathan	Chief R&D Officer	Nov 25 '25	Sale	54.28	1,157	62,802	18,971	Nov 25 08:30 PM
Wilson Mark Andrew	Chief Legal Officer	Nov 25 '25	Sale	54.28	630	34,196	21,585	Nov 25 08:29 PM
ROBIN HOWARD W	President & CEO	Nov 25 '25	Sale	54.28	2,207	119,796	54,245	Nov 25 08:28 PM
ROBIN HOWARD W	Officer	Nov 25 '25	Proposed Sale	58.82	2,207	129,812		Nov 25 03:35 PM
Wilson Mark Andrew	Officer	Nov 25 '25	Proposed Sale	58.82	630	37,056		Nov 25 03:32 PM
Zalevsky Jonathan	Officer	Nov 25 '25	Proposed Sale	58.82	1,157	68,053		Nov 25 03:28 PM
ROBIN HOWARD W	President & CEO	Sep 09 '25	Sale	46.69	6,666	311,214	49,342	Sep 11 09:01 PM
ROBIN HOWARD W	Officer	Sep 09 '25	Proposed Sale	46.69	6,666	311,205		Sep 09 04:57 PM
Zalevsky Jonathan	Chief R&D Officer	Sep 04 '25	Sale	33.52	1,721	57,693	17,462	Sep 08 08:32 PM
ROBIN HOWARD W	President & CEO	Sep 05 '25	Sale	38.53	6,666	256,851	56,008	Sep 08 08:31 PM
ROBIN HOWARD W	President & CEO	Sep 04 '25	Sale	33.70	5,166	174,108	62,674	Sep 08 08:31 PM
ROBIN HOWARD W	Officer	Sep 05 '25	Proposed Sale	38.53	6,666	256,838		Sep 05 04:37 PM
Zalevsky Jonathan	Chief R&D Officer	Sep 02 '25	Sale	30.10	485	14,598	19,183	Sep 04 09:02 PM
ROBIN HOWARD W	President & CEO	Sep 02 '25	Sale	30.16	1,500	45,240	67,840	Sep 04 09:01 PM
ROBIN HOWARD W	Officer	Sep 04 '25	Proposed Sale	33.70	5,166	174,119		Sep 04 05:06 PM
Zalevsky Jonathan	Officer	Sep 04 '25	Proposed Sale	33.52	1,721	57,688		Sep 04 04:19 PM
Zalevsky Jonathan	Officer	Sep 02 '25	Proposed Sale	30.10	485	14,600		Sep 02 04:45 PM
ROBIN HOWARD W	Officer	Sep 02 '25	Proposed Sale	30.16	1,500	45,244		Sep 02 04:42 PM
Zalevsky Jonathan	Chief R&D Officer	Aug 19 '25	Sale	26.59	725	19,278	19,668	Aug 21 09:05 PM
Wilson Mark Andrew	Chief Legal Officer	Aug 19 '25	Sale	26.59	676	17,975	20,312	Aug 21 09:04 PM
ROBIN HOWARD W	President & CEO	Aug 19 '25	Sale	26.59	1,573	41,826	69,340	Aug 21 09:03 PM
ROBIN HOWARD W	Officer	Aug 19 '25	Proposed Sale	26.59	1,573	41,826		Aug 19 03:24 PM
Wilson Mark Andrew	Officer	Aug 19 '25	Proposed Sale	26.59	676	17,975		Aug 19 03:24 PM
Zalevsky Jonathan	Officer	Aug 19 '25	Proposed Sale	26.59	725	19,278		Aug 19 03:20 PM
Zalevsky Jonathan	Chief R&D Officer	May 19 '25	Sale	0.67	10,712	7,177	305,892	May 21 08:08 PM
Wilson Mark Andrew	Chief Legal Officer	May 19 '25	Sale	0.67	9,996	6,697	314,296	May 21 08:07 PM
ROBIN HOWARD W	President & CEO	May 19 '25	Sale	0.67	23,208	15,549	1,063,693	May 21 08:07 PM
Zalevsky Jonathan	Officer	May 19 '25	Proposed Sale	0.67	10,712	7,191		May 19 03:49 PM
Wilson Mark Andrew	Officer	May 19 '25	Proposed Sale	0.67	9,996	6,710		May 19 03:44 PM
ROBIN HOWARD W	Officer	May 19 '25	Proposed Sale	0.67	23,208	15,580		May 19 03:40 PM
Zalevsky Jonathan	Chief R&D Officer	Feb 19 '25	Sale	1.01	10,300	10,403	316,604	Feb 21 06:07 PM
Wilson Mark Andrew	Chief Legal Officer	Feb 19 '25	Sale	1.01	11,040	11,150	324,292	Feb 21 06:06 PM
ROBIN HOWARD W	President & CEO	Feb 19 '25	Sale	1.01	23,774	24,012	1,086,901	Feb 21 06:04 PM
Wilson Mark Andrew	Officer	Feb 19 '25	Proposed Sale	1.01	11,040	11,137		Feb 19 03:27 PM
ROBIN HOWARD W	Officer	Feb 19 '25	Proposed Sale	1.01	23,774	23,983		Feb 19 03:21 PM
Zalevsky Jonathan	Officer	Feb 19 '25	Proposed Sale	1.01	10,300	10,391		Feb 19 03:18 PM

VCYT

Veracyte Inc

NKTR

Nektar Therapeutics

Upgrade your FINVIZ experience